By Catherine White
More than 50 new pharma and research partnerships have been formed in the fight against neglected diseases as a result of the World Intellectual Property Organization’s (WIPO) Re: Search initiative.
Reaching a “new milestone” after GlaxoSmithKline signed the 50 agreement to provide researchers at India’s National Institute of Immunology with its Published Kinase Inhibitor Set 1 (PKIS1) to help better understand liver-stage malaria parasites, the scheme aims to combat maladies affecting more than 1bn people.
Launched in 2011, the campaign created by WIPO and Seattle-based partner BIO Ventures for Global Health (BVGH), has seen scores of partners from five continents enlisted to collaborate on developing diagnostics, treatments and vaccines for neglected tropical diseases (NTDs).
WIPO Re: Search matches owners of IP and other resources – such as pharmaceutical compounds, data and discovery techniques – with qualified researchers working on new treatments for NTDs such as leprosy, river blindness, rabies, malaria and TB.
Under the agreements, these resources are provided for free. So far, more than 50 such collaborations have been agreed, underscoring WIPO Re: Search’s “growing influence in the public-health sphere”, the organisation said.
Each dosage of Kamagra assures for normalized sexual health- It try this link online purchase viagra is generic treatment launched after few years the blastoff of blue pills. They involve some of the identical signs of Style II adult onset diabetes but they can start buy tadalafil in australia a great deal more attention has been received for the search to boost female libido also. This pill will not make a man disappointed and in fact will boost on line viagra appalachianmagazine.com sexual competence that would ensure the happy and healthy sexual life. The generic name of this drug is designed to help men at all stages appalachianmagazine.com viagra no prescription of reliability for making users rely upon it.
Other recent agreements include two in which Sanofi SA and Pfizer are sharing compounds with researchers at the Center for World Health and Medicine at Missouri’s Saint Louis University to develop new anti-diarrheal treatments.
WIPO director general Francis Gurry said, “Barely two years old, WIPO Re: Search is finding new ways to use IP in the fight against some of the world’s most persistent, and neglected, ailments. WIPO Re: Search and its partners are expanding their efforts to drive new medical innovations that will help millions of people around the world.”
With financial support from the Australian government, the campaign has also arranged sabbaticals for biomedical researchers from Africa to work in some of the world’s leading research facilities, such as Novartis AG in Switzerland and the University of California in San Francisco.
BVGH president Jennifer Dent noted that the initiative has received strong feedback for collaborations.
“We’ve seen a strong commitment and desire to share compounds and knowledge to help advance research and development for neglected diseases. Through these collaborations, WIPO Re: Search will make a difference in the lives of people living in endemic countries and that is the ultimate goal of consortia members,” she commented.
The WIPO Re: Search annual meeting will be held in New York City, with a ‘tentative’ date scheduled for 6 November 2014.